SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Halstead S. ( 2008) Pathogenesis: risk factors prior to infection. In: Halstead S., Pasvol G., Hoffman S.L., eds. Dengue, London: Imperial College Press, pp. 21956.
  • 2
    Chen H.W., Liu S.J., Li Y.S., Liu H.H., Tsai J.P., Chiang C.Y., Chen M.Y., Hwang C.S., Huang C.C., Hu H.M., Chung H.H., Wu S.H., Chong P., Leng C.H., Pan C.H. ( 2013) A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol 158: 152331.
  • 3
    Simmons M., Murphy G.S., Hayes C.G. ( 2001) Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 65: 15961.
  • 4
    Valdes I., Bernardo L., Gil L., Pavon A., Lazo L., Lopez C., Romero Y., Menendez I., Falcon V., Betancourt L., Martin J., Chinea G., Silva R., Guzman M.G., Guillen G., Hermida L. ( 2009) A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 394: 24958.
  • 5
    Chiang C.Y., Huang M.H., Pan C.H., Hsieh C.H., Chen M.Y., Liu H.H., Tsai J.P., Liu S.J., Chong P., Leng C.H., Chen H.W. ( 2013) Induction of robust immunity by the emulsification of recombinant lipidated dengue-1 envelope protein domain III. Microbes Infect 15: 71928.
  • 6
    Chen Y., Maguire T., Marks R.M. ( 1996) Demonstration of binding of dengue virus envelope protein to target cells. J Virol 70: 876572.
  • 7
    Wahala W.M., Huang C., Butrapet S., White L.J., De Silva A.M. ( 2012) Recombinant dengue type 2 viruses with altered E protein domain III epitopes are efficiently neutralized by human immune sera. J Virol 86: 401923.
  • 8
    Hermida L., Rodriguez R., Lazo L., Silva R., Zulueta A., Chinea G., Lopez C., Guzman M.G., Guillen G. ( 2004) A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 115: 419.
  • 9
    Hermida L., Rodriguez R., Lazo L., Bernardo L., Silva R., Zulueta A., Lopez C., Martin J., Valdes I., Del R.D., Guillen G., Guzman M.G. ( 2004) A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem 39: 10714.
  • 10
    Zulueta A., Martin J., Hermida L., Alvarez M., Valdes I., Prado I., Chinea G., Rosario D., Guillen G., Guzman M.G. ( 2006) Amino acid changes in the recombinant dengue 3 envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res 121: 6573.
  • 11
    Lazo L., Zulueta A., Hermida L., Blanco A., Sanchez J., Valdes I., Gil L., Lopez C., Romero Y., Guzman M.G., Guillen G. ( 2009) Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem 52: 26571.
  • 12
    Gonzalez S., Alvarez A., Caballero E., Vina L., Guillen G., Silva R. ( 2000) P64k meningococcal protein as immunological carrier for weak immunogens. Scand J Immunol 52: 1136.
  • 13
    Mulet A., Garrido G., Alvarez A., Menendez T., Bohmer F.D., Perez R., Fernandez L.E. ( 2006) The enlargement of the hormone immune deprivation concept to the blocking of TGFalpha-autocrine loop: EGFR signaling inhibition. Cancer Immunol Immunother 55: 62838.
  • 14
    Perez A., Dickinson F., Cinza Z., Ruiz A., Serrano T., Sosa J., Gonzalez S., Gutierrez Y., Nazabal C., Gutierrez O., Guzman D., Diaz M., Delgado M., Caballero E., Sardinas G., Alvarez A., Martin A., Guillen G., Silva R. ( 2001) Safety and preliminary immunogenicity of the recombinant outer membrane protein P64k of Neisseria meningitidis in human volunteers. Biotechnol Appl Biochem 34: 1215.
  • 15
    Bernardo L., Izquierdo A., Alvarez M., Rosario D., Prado I., Lopez C., Martinez R., Castro J., Santana E., Hermida L., Guillen G., Guzman M.G. ( 2008) Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 80: 1949.
  • 16
    Hermida L., Bernardo L., Martin J., Alvarez M., Prado I., Lopez C., Sierra B.L., Martinez R., Rodriguez R., Zulueta A., Perez A.B., Lazo L., Rosario D., Guillen G., Guzman M.G. ( 2006) A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24: 316571.
  • 17
    Goncalvez A.P., Escalante A.A., Pujol F.H., Ludert J.E., Tovar D., Salas R.A., Liprandi F. ( 2002) Diversity and evolution of the envelope gene of dengue virus type 1. Virology 303: 1109.
  • 18
    Rodriguez-Roche R., Alvarez M., Holmes E.C., Bernardo L., Kouri G., Gould E.A., Halstead S., Guzman M.G. ( 2005) Dengue virus type 3, Cuba, 2000–2002. Emerg Infect Dis 11: 7734.
  • 19
    Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perreault J.R., Thumar B., Men R., Lai C.J., Elkins W.R., Chanock R.M., Murphy B.R., Whitehead S.S. ( 2001) Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg 65: 40513.
  • 20
    Clarke D.H., Casals J. ( 1958) Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 7: 56173.
  • 21
    Zulueta A., Hermida L., Lazo L., Valdes I., Rodriguez R., Lopez C., Silva R., Rosario D., Martin J., Guzman M.G., Guillen G. ( 2003) The fusion site of envelope fragments from each serotype of dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem Biophys Res Commun 308: 61926.
  • 22
    Lazo L., Gil L., Lopez C., Valdes I., Blanco A., Pavon A., Romero Y., Guzman M.G., Guillen G., Hermida L. ( 2012) A vaccine formulation consisting of nucleocapsid-like particles from dengue-2 and the fusion protein P64k-domain III from dengue-1 induces a protective immune response against the homologous serotypes in mice. Acta Trop 124: 10712.
  • 23
    Morens D.M., Halstead S.B., Repik P.M., Putvatana R., Raybourne N. ( 1985) Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22: 2504.
  • 24
    Clements D.E., Coller B.A., Lieberman M.M., Ogata S., Wang G., Harada K.E., Putnak J.R., Ivy J.M., Mcdonell M., Bignami G.S., Peters I.D., Leung J., Weeks-Levy C., Nakano E.T., Humphreys T. ( 2010) Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28: 270515.
  • 25
    Leng C.H., Liu S.J., Tsai J.P., Li Y.S., Chen M.Y., Liu H.H., Lien S.P., Yueh A., Hsiao K.N., Lai L.W., Liu F.C., Chong P., Chen H.W. ( 2009) A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 11: 28895.
  • 26
    Chiang C.Y., Liu S.J., Tsai J.P., Li Y.S., Chen M.Y., Liu H.H., Chong P., Leng C.H., Chen H.W. ( 2011) A novel single-dose dengue subunit vaccine induces memory immune responses. PLoS One 6: E23319.
  • 27
    Chiang C.Y., Huang M.H., Hsieh C.H., Chen M.Y., Liu H.H., Tsai J.P., Li Y.S., Chang C.Y., Liu S.J., Chong P., Leng C.H., Chen H.W. ( 2012) Dengue-1 envelope protein domain III along with PELC and CPG oligodeoxynucleotides synergistically enhances immune responses. PLoS Negl Trop Dis 6: E1645.
  • 28
    Lazo L., Gil L., Lopez C., Valdes I., Marcos E., Alvarez M., Blanco A., Romero Y., Falcon V., Guzman M.G., Guillen G., Hermida L. ( 2010) Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. Arch Virol 155: 158795.
  • 29
    Gil L., Lopez C., Blanco A., Lazo L., Martin J., Valdes I., Romero Y., Figueroa Y., Guillen G., Hermida L. ( 2009) The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol 22: 2330.
  • 30
    Van Der Most R.G., Murali-Krishna K., Ahmed R., Strauss J.H. ( 2000) Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J Virol 74: 8094101.
  • 31
    Van Der Most R.G., Murali-Krishna K., Ahmed R. ( 2003) Prolonged presence of effector-memory CD8 T cells in the central nervous system after dengue virus encephalitis. Int Immunol 15: 11925.
  • 32
    Yauch L.E., Zellweger R.M., Kotturi M.F., Qutubuddin A., Sidney J., Peters B., Prestwood T.R., Sette A., Shresta S. ( 2009) A protective role for dengue virus-specific CD8+ T Cells. J Immunol 182: 486573.
  • 33
    Valdes I., Hermida L., Gil L., Lazo L., Castro J., Martin J., Bernardo L., Lopez C., Niebla O., Menendez T., Romero Y., Sanchez J., Guzman M.G., Guillen G. ( 2010) Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int J Infect Dis 14: E37783.
  • 34
    Brandler S., Lucas-Hourani M., Moris A., Frenkiel M.P., Combredet C., Fevrier M., Bedouelle H., Schwartz O., Despres P., Tangy F. ( 2007) Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 1: E96.